semaglutide cardiovascular outcomes news 2025 risk reduction with once-weekly in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial Cardiovascular Disease | Ozempic® (semaglutide)

Zealthy does not require a video visit to get a prescription

Diabetologia (2003) 46:22230

Prepare to embark on a transformative path that promises sustainable and lasting results, allowing you to finally take control of your weight and revolutionize your life for the better

What this post covers: Where GLP-1 receptors sit in the brain and why that matters for reward and compulsion The clinical trial pipeline for GLP-1 agonists in addiction (alcohol, nicotine, opioids) Why anhedonia may be a dosing problem, not a drug problem, and the ziprasidone parallel Real-world observations from low-dose tirzepatide combined with ketogenic diets The scope-of-practice question: should psychiatrists be prescribing GLP-1 agonists